Insmed Incorporated (NASDAQ:INSM) is Cutter Capital Management LP's 8th Largest Position

Cutter Capital Management LP lowered its stake in shares of Insmed Incorporated (NASDAQ:INSM - Free Report) by 2.3% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 210,884 shares of the biopharmaceutical company's stock after selling 5,000 shares during the quarter. Insmed accounts for 6.0% of Cutter Capital Management LP's investment portfolio, making the stock its 8th biggest position. Cutter Capital Management LP owned 0.12% of Insmed worth $14,559,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Darwin Global Management Ltd. raised its holdings in shares of Insmed by 23.5% during the fourth quarter. Darwin Global Management Ltd. now owns 12,960,538 shares of the biopharmaceutical company's stock valued at $894,796,000 after purchasing an additional 2,463,261 shares during the last quarter. Norges Bank bought a new position in shares of Insmed in the fourth quarter worth approximately $126,606,000. Vanguard Group Inc. increased its stake in Insmed by 6.3% in the 4th quarter. Vanguard Group Inc. now owns 18,218,973 shares of the biopharmaceutical company's stock worth $1,257,838,000 after buying an additional 1,075,796 shares in the last quarter. Brown Advisory Inc. bought a new position in Insmed in the 4th quarter worth approximately $45,773,000. Finally, Adage Capital Partners GP L.L.C. lifted its holdings in shares of Insmed by 59.6% in the fourth quarter. Adage Capital Partners GP L.L.C. now owns 1,647,562 shares of the biopharmaceutical company's stock worth $113,748,000 after buying an additional 615,000 shares in the last quarter.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on INSM shares. Stifel Nicolaus dropped their price objective on shares of Insmed from $97.00 to $96.00 and set a "buy" rating for the company in a research note on Friday, February 21st. UBS Group decreased their price target on Insmed from $110.00 to $109.00 and set a "buy" rating on the stock in a report on Friday. Wells Fargo & Company lifted their price objective on shares of Insmed from $85.00 to $107.00 and gave the stock an "overweight" rating in a research note on Wednesday, February 19th. Bank of America raised their target price on shares of Insmed from $92.00 to $96.00 and gave the stock a "buy" rating in a report on Thursday, March 20th. Finally, Cantor Fitzgerald reissued an "overweight" rating on shares of Insmed in a research report on Wednesday, February 19th. One research analyst has rated the stock with a sell rating and sixteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $93.93.

Insmed Stock Performance

NASDAQ:INSM traded down $0.55 during trading hours on Friday, hitting $65.08. 2,388,354 shares of the company were exchanged, compared to its average volume of 2,324,735. The company has a debt-to-equity ratio of 2.03, a current ratio of 6.37 and a quick ratio of 5.99. Insmed Incorporated has a 52-week low of $21.92 and a 52-week high of $84.91. The stock has a market capitalization of $11.83 billion, a price-to-earnings ratio of -11.64 and a beta of 0.84. The company's 50 day moving average price is $72.61 and its 200-day moving average price is $73.32.

Insmed (NASDAQ:INSM - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported ($1.42) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.36) by ($0.06). The firm had revenue of $92.82 million during the quarter, compared to analysts' expectations of $91.63 million. Insmed had a negative return on equity of 4,773.73% and a negative net margin of 251.24%. The company's revenue for the quarter was up 22.9% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($1.06) earnings per share. As a group, research analysts forecast that Insmed Incorporated will post -4.56 earnings per share for the current year.

Insider Transactions at Insmed

In other Insmed news, CEO William Lewis sold 6,830 shares of the company's stock in a transaction on Thursday, May 1st. The stock was sold at an average price of $72.57, for a total value of $495,653.10. Following the completion of the sale, the chief executive officer now directly owns 233,924 shares in the company, valued at $16,975,864.68. This represents a 2.84 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Roger Adsett sold 42,975 shares of Insmed stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $78.61, for a total transaction of $3,378,264.75. Following the transaction, the chief operating officer now directly owns 146,082 shares in the company, valued at $11,483,506.02. This trade represents a 22.73 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 182,337 shares of company stock worth $14,284,557 over the last quarter. 3.00% of the stock is currently owned by insiders.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.